BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 22416776)

  • 1. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCCN Task Force Report: mTOR inhibition in solid tumors.
    Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
    J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
    Khokhar NZ; Altman JK; Platanias LC
    Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
    Diaz-Padilla I; Duran I; Clarke BA; Oza AM
    Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
    Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
    Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
    Chapuis N; Tamburini J; Green AS; Willems L; Bardet V; Park S; Lacombe C; Mayeux P; Bouscary D
    Leukemia; 2010 Oct; 24(10):1686-99. PubMed ID: 20703258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
    Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
    Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR as a therapeutic target in patients with gastric cancer.
    Al-Batran SE; Ducreux M; Ohtsu A
    Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in diffuse large B-cell lymphomas.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.